Anshu Joshi

TL;DR: In this article , the SARS-CoV-2 Omicron BA has multiple mutations in its spike protein, which increases evasion of therapeutic monoclonal and vaccine-elicited polyclonal neutralizing antibodies after two doses.

TL;DR: In this paper , the authors demonstrate that breakthrough infections induce serum-binding and neutralizing antibody responses that are markedly more potent, durable, and resilient to spike mutations observed in variants than those in subjects who received only 2 doses of vaccine.

TL;DR: The isolation and characterization of a human monoclonal antibody, designated S2K146, that broadly neutralizes viruses belonging to SARS-CoV– and SARV-2–related sarbecovirus clades, which use angiotensin-converting enzyme 2 (ACE2) as an entry receptor.

TL;DR: Structural and functional analyses show that the fusion peptide-specific mAbs bind with different modalities to a cryptic epitope, which is hidden in prefusion stabilized S, and becomes exposed upon binding of angiotensin-converting enzyme 2 (ACE2) or ACE2-mimicking mAbs.